PanGen Biotech Statistics

Total Valuation

PanGen Biotech has a market cap or net worth of KRW 85.55 billion. The enterprise value is 75.35 billion.

Market Cap	85.55B
Enterprise Value	75.35B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

PanGen Biotech has 13.49 million shares outstanding. The number of shares has increased by 10.08% in one year.

Current Share Class	13.49M
Shares Outstanding	13.49M
Shares Change (YoY)	+10.08%
Shares Change (QoQ)	+5.58%
Owned by Insiders (%)	4.06%
Owned by Institutions (%)	n/a
Float	6.36M

Valuation Ratios

The trailing PE ratio is 46.71.

PE Ratio	46.71
Forward PE	n/a
PS Ratio	5.84
PB Ratio	3.34
P/TBV Ratio	3.44
P/FCF Ratio	41.38
P/OCF Ratio	32.89
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.34, with an EV/FCF ratio of 36.45.

EV / Earnings	46.71
EV / Sales	5.15
EV / EBITDA	24.34
EV / EBIT	45.93
EV / FCF	36.45

Financial Position

The company has a current ratio of 8.79, with a Debt / Equity ratio of 0.03.

Current Ratio	8.79
Quick Ratio	5.86
Debt / Equity	0.03
Debt / EBITDA	0.28
Debt / FCF	0.41
Interest Coverage	6.06

Financial Efficiency

Return on equity (ROE) is 7.63% and return on invested capital (ROIC) is 4.53%.

Return on Equity (ROE)	7.63%
Return on Assets (ROA)	3.71%
Return on Invested Capital (ROIC)	4.53%
Return on Capital Employed (ROCE)	5.76%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.53
Inventory Turnover	1.32

Taxes

In the past 12 months, PanGen Biotech has paid 73.53 million in taxes.

Income Tax	73.53M
Effective Tax Rate	4.36%

Stock Price Statistics

The stock price has increased by +11.54% in the last 52 weeks. The beta is -0.00, so PanGen Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.00
52-Week Price Change	+11.54%
50-Day Moving Average	5,757.00
200-Day Moving Average	5,234.15
Relative Strength Index (RSI)	55.88
Average Volume (20 Days)	26,333

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PanGen Biotech had revenue of KRW 14.64 billion and earned 1.61 billion in profits. Earnings per share was 135.74.

Revenue	14.64B
Gross Profit	5.73B
Operating Income	1.64B
Pretax Income	1.69B
Net Income	1.61B
EBITDA	3.10B
EBIT	1.64B
Earnings Per Share (EPS)	135.74

Full Income Statement

Balance Sheet

The company has 11.05 billion in cash and 851.84 million in debt, giving a net cash position of 10.20 billion or 756.03 per share.

Cash & Cash Equivalents	11.05B
Total Debt	851.84M
Net Cash	10.20B
Net Cash Per Share	756.03
Equity (Book Value)	25.64B
Book Value Per Share	1,988.26
Working Capital	18.78B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.60 billion and capital expenditures -533.47 million, giving a free cash flow of 2.07 billion.

Operating Cash Flow	2.60B
Capital Expenditures	-533.47M
Free Cash Flow	2.07B
FCF Per Share	153.20

Full Cash Flow Statement

Margins

Gross margin is 39.17%, with operating and profit margins of 11.21% and 11.02%.

Gross Margin	39.17%
Operating Margin	11.21%
Pretax Margin	11.52%
Profit Margin	11.02%
EBITDA Margin	21.14%
EBIT Margin	11.21%
FCF Margin	14.12%

Dividends & Yields

PanGen Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.08%
Shareholder Yield	n/a
Earnings Yield	1.89%
FCF Yield	2.42%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PanGen Biotech has an Altman Z-Score of 6.14 and a Piotroski F-Score of 7.

Altman Z-Score	6.14
Piotroski F-Score	7